Anti-inflammatory therapy for COVID-19 infection: the case for colchicine
Top Cited Papers
Open Access
- 8 December 2020
- journal article
- review article
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 80 (5), 550-557
- https://doi.org/10.1136/annrheumdis-2020-219174
Abstract
The search for effective COVID-19 management strategies continues to evolve. Current understanding of SARS-CoV-2 mechanisms suggests a central role for exaggerated activation of the innate immune system as an important contributor to COVID-19 adverse outcomes. The actions of colchicine, one of the oldest anti-inflammatory therapeutics, target multiple mechanisms associated with COVID-19 excessive inflammation. While many COVID-19 trials have sought to manipulate SARS-CoV-2 or dampen the inflammatory response once patients are hospitalised, few examine therapeutics to prevent the need for hospitalisation. Colchicine is easily administered, generally well tolerated and inexpensive, and holds particular promise to reduce the risk of hospitalisation and mortality due to COVID-19 in the outpatient setting. Successful outpatient treatment of COVID-19 could greatly reduce morbidity, mortality and the demand for rare or expensive care resources (front-line healthcare workers, hospital beds, ventilators, biological therapies), to the benefit of both resource-replete and resource-poor regions.Keywords
This publication has 76 references indexed in Scilit:
- Colchicine Use Is Associated with Decreased Prevalence of Myocardial Infarction in Patients with GoutThe Journal of Rheumatology, 2012
- The InflammasomesCell, 2010
- Gout-associated uric acid crystals activate the NALP3 inflammasomeNature, 2006
- Two Probable Cases of Serious Drug Interaction Between Clarithromycin and ColchicineSouthern Medical Journal, 2005
- Natural regulatory T cells in infectious diseaseNature Immunology, 2005
- Does the lack of the P-glycoprotein efflux pump in neutrophils explain the efficacy of colchicine in familial Mediterranean fever and other inflammatory diseases?Medical Hypotheses, 1998
- Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils.JCI Insight, 1995
- Defensins. Natural peptide antibiotics of human neutrophils.JCI Insight, 1985
- Prolonged reduction in polymorphonuclear adhesion following oral colchicine.Annals Of The Rheumatic Diseases, 1981
- Platelets and MicrotubulesJCI Insight, 1980